Therapeutic vaccination with p24-VLP and zidovudine augments HIV- specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals

AIDS Research and Human Retroviruses

Volumn 15, Issue 2, 1999, Pages 105-113

  Benson, Elizabeth M ^a   Clarkson, Janett ^a   Law, Matthew ^b   Marshall, Philip ^a   Kelleher, Anthony D ^b   Smith, Don E ^c   Patou, Gary ^d   Stewart, Graeme J ^a   Cooper, David A ^b   Ffrench, Rosemary A ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN P24; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; NEOPTERIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS LOAD; VIRUS PARTICLE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ANTI-HIV AGENTS; CD4-CD8 RATIO; COHORT STUDIES; FEMALE; HIV; HIV CORE PROTEIN P24; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; ZIDOVUDINE;

EID: 0033585497     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311538     Document Type: Article

References (50)

1. Zinkernagel RM and Doherty PC: H-2 compatibility requirement for T-cell mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med 1975;141:1427-1436.
2. Luckacker AE, Braciale VL, and Braciale TJ: In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984;160(3):814-826.
3. Cannon MJ, Openshaw PJM, and Askonas B: Cytotoxic cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988;168:1163-1168.
4. Bonneau RH and Jennings SR: Herpes simplex virus-specific cytolytic T lymphocytes restricted to a normally low responder H-2 allele are protective in vivo. Virology 1990;174(2):599-604.
5. McMichael AJ, Gotch FM, Noble GR, and Beare PAS: Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309:13-17.
6. Reusser P, Riddell SR, Meyers JD, and Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78(5): 1373-1380.
7. Rooney CM, Smith CA, Ng CY, et al.: Use of gene-modified virus-specific T lymphocytes to control EBV-related lymphoproliferation. Lancet 1995;345:9-13.
8. Walter EA, Greenberg PD, Gilbert MJ, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333(16):1038-1044.
9. Rowland-Jones SL, Sutton J, Ariyoshi K, et al.: HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women. Nature Med 1995;1(1):59-64.
10. Fowke K, Nagelkerke N, Kimani J, et al.: Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996;348(9038):1347-1351.
11. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Viro 1994; 68(7):4650-4655.
12. + cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68(9):6103-6110.
13. Musey L, Hughes J, Schacker T, Shea T, Corey L, and McElrath MJ: Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337(18):1267-1274.
14. Wolinsky SM, Korber BTM, Neumann AU, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-540.
15. Nowak MA, May RM, Phillips RE, et al.: Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (London) 1995;375(6532):606-611.
16. Goulder PJ, Phillips RE, Colbert RA, et al.: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med 1997;3(2):212-217.
17. Borrow P, Lewicki H, Wei X, et al.: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 1997;3:205-211.
18. Redfield RR, Birx DL, Ketter N, et al.: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-1684.
19. Wahren B, Bratt G, Persson C, et al.: Improved cell mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994;7:220-229.
20. Kundu SK, Katzenstein D, Moses LE, and Merigan TC: Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992;89:1204-1208.
21. Turner JL, Trauger RJ, Daigle AE, and Carlo DJ: HIV-1 immunogen induction of HIV-1-specific delayed type hypersensitivity: results of a double blind, adjuvant-controlled, dose ranging trial. AIDS 1994;8:1429-1435.
22. Trauger RJ, Ferre F, Daigle AE, et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994;169:1256-1264.
23. Adams SE, Dawson KM, Gull K, Kingsman SM, and Kingsman AJ: The expression of hybrid HIV:Ty virus-like particles in yeast. Nature (London) 1987;329:68-70.
24. Weber J, Cheinsong-Popov R, Callow D, et al.: Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995;13:831-834.
25. Klein MR, Veenstra J, Holwerda AM, et al.: Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV Type 1-seropositive individuals. AIDS Res Hum Retroviruses 1996;13(5):393-399.
26. Kelleher AD, Roggensack M, Jaramillo AB, et al.: Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus like particle, combined with zidovudine, in asymptomatic patients. AIDS 1998;12:175-182.
27. Matthew JNS, Altman DG, Campbell MJ, and Royston P: Analysis of serial measurements in medical research. Br Med J 1990; 300:230-235.
28. Hoffenbach A, Langlande-Demoyen P, Dadaglio G, et al.: Unusually high frequencies of HIV-specific cytotoxic T-lymphocytes in humans. J Immunol 1989;142:452-462.
29. Dadaglio G, Michel F, Langlade-Demoyen P, et al.: Enhancement of HIV-specific cytotoxic T lymphocyte responses by zidovudine (AZT) treatment. Clin Exp Immunol 1992;87:7-14.
30. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined anti-retroviral therapy in CD4+ T-cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
31. Kelleher AD, Carr A, Zaunders J, and Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-329.
32. Schnittman SM and Fox L: Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent anti-retroviral therapies. Clues from the fourth conference on retroviruses and opportunistic diseases. AIDS Res Hum Retroviruses 1997;13:815-818.
33. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997;3:533-540.
34. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
35. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, et al.: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2108.
36. + human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248:1234-1237.
37. IIIB ENV/Rev proteins. AIDS 1995;9:43-50.
38. McKallip RJ, Nagarkatti M, and Nagarkatti PS: Immunotoxicity of AZT: Inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp120 of human immunodeficiency virus. Toxicol Appl. Pharmacol 1995;131:53-62.
39. Brewer JM, Conacher M, Satoskar A, Bluethmann H, and Alexander J: In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062-2066.
40. Riviere Y, Tanneau-Salvadori F, Regnault A, et al.: Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: Distinct types of effector cells mediate killing of targets expressing Gag and Env proteins. J Virol 1989;63:2270-2277.
41. 3 CD4 lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996;1336-1346.
42. Wahren B, Bratt G, Persson C, et al.: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994;7:220-229.
43. Hamilton, B, Byrn R, Giorgi J, and Izu A: A T-cell proliferation as a measure of the immunogenicity of HIV/gp120 vaccine in seropositive subjects. In: IXth International Conference on AIDS, Berlin 1993.
44. Eron JJ Jr, Ashby MA, Giordano MF, et al.: Randomised trial of Mn rgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996;348:1547-1551.
45. Zinkernagel RM: Are HIV-specific CTL responses salutary or pathogenic? Curr Opin Immunol 1995;7:462-470.
46. Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
47. Koenig S, Conley AJ, Yambasu A, et al.: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Med 1995;4:330-336.
48. Klenerman P, Rowland-Jones S, McAdam S, et al.: Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature (London) 1994;369:403-407.
49. Tsomides TJ, Aldovini A, Johnson RP, et al.: Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 1994;180:1283-1293.
50. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, and Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.